Influenza A virus H1N1 vaccine - Seqirus

Drug Profile

Influenza A virus H1N1 vaccine - Seqirus

Alternative Names: A(H1N1) influenza vaccine - Seqirus; A/H1N1-SOIV (swine flu) vaccine - Seqirus; A/H1N1v vaccines - Seqirus; Adjuvanted cell culture-based influenza A H1N1 (2009) monovalent vaccine (Celtura®) - Seqirus; Celtura; Fluvirin A(H1N1) monovalent vaccine - Seqirus; Fluvirin A/H1N1; Focetria; H1N1 pandemic influenza virus vaccine - Seqirus; MF59-eH1N1 - Seqirus; Monovalent A/H1N1 influenza vaccine - Seqirus; Swine flu vaccine - Seqirus; Swine-origin influenza A/H1N1 virus monovalent subunit vaccine - Seqirus

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Seqirus
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 02 Jun 2017 No recent reports on development identified - Registered for Influenza-A virus H1N1 subtype (Prevention) in Iceland, Norway, and Turkey (IM)
  • 09 Nov 2015 CSL’s influenza vaccine business started operating under the brand name Seqirus
  • 18 Jul 2011 US FDA approves Fluvirin® for the 2011-2012 influenza season in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top